Abstract:Background: Food allergy prevalence has continued to rise over the past decade. While studies have reported threshold doses for multiple foods, large-scale multi-food allergen studies are lacking. Our goal was to identify threshold dose distributions and predictors of severe reactions during blinded oral food challenges (OFCs) in multi-food allergic patients. Methods: A retrospective chart review was performed on all Stanford-initiated clinical protocols involving standardized screening OFCs to any of 11 food allergens at 7 sites. Interval-censoring survival analysis was used to calculate eliciting dose (ED) curves for each food. Changes in severity and ED were also analyzed among participants who had repeated challenges to the same food. Results: Of 428 participants, 410 (96%) had at least one positive challenge (1445 standardized OFCs with 1054 total positive challenges). Participants undergoing peanut challenges had the highest ED50 (29.9 mg), while those challenged with egg or pistachio had the lowest (7.07 or 1.7 mg, respectively). The most common adverse event was skin related (54%), followed by gastrointestinal (GI) events (33%). A history of asthma was associated with a significantly higher risk of a severe reaction (hazard ratio [HR]: 2.37, 95% confidence interval [CI]: 1.36, 4.13). Higher values of allergen-specific IgE (sIgE) and sIgE to total IgE ratio (sIgEr) were also associated with higher risk of a severe reaction (1.49 [1.19, 1.85] and 1.84 [1.30, 2.59], respectively). Participants undergoing cashew, peanut, pecan, sesame, and walnut challenges had more severe reactions as ED increased. In participants who underwent repeat challenges, the ED did not change (p = 0.66), but reactions were more severe (p = 0.02). Conclusions: Participants with a history of asthma, high sIgEr, and/or high values of sIgE were found to be at higher risk for severe reactions during food challenges. These findings may help to optimize food challenge dosing schemes in multi-food allergic, atopic patients, specifically at lower doses where the majority of reactions occur. Trials Registration Number: ClinicalTrials. gov number NCT03539692; https://clinicaltrials.gov/ct2/show/NCT03539692.

The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy

PSY2 THE ESTIMATED RISK REDUCTION OF ANAPHYLACTIC REACTIONS ASSOCIATED WITH AR101 ORAL IMMUNOTHERAPY FOLLOWING ACCIDENTAL PEANUT EXPOSURE: AN ANALYSIS BASED ON CLINICAL TRIAL DATA

Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial

Effect of Avoidance on Peanut Allergy after Early Peanut Consumption

From Skin to Solution: Exploring Epicutaneous Immunotherapy for Peanut Allergy—A Systematic Review and Meta-Analysis

Safety and adherence of early oral immunotherapy for peanut allergy in a primary care setting: a retrospective cross-sectional study

Optimising the management of peanut allergy by targeting immune plasticity

Eliciting Dose and Safety Outcomes From a Large Dataset of Standardized Multiple Food Challenges

Early Peanut Immunotherapy in Children (EPIC) trial: protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age

Risk subgroups and intervention effects among infants at high risk for peanut allergy: A model for clinical decision making

Prevalence and Characteristics of Accidental Ingestions Among Pediatric Food Allergy Patients

Peanut Immunotherapy Increases Allergic and Anaphylactic Reactions, Finds Review

Efficacy of Allergen-Specific Immunotherapy for Peanut Allergy: a Meta-Analysis of Randomized Controlled Trials.

Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy

Food allergy: Epicutaneous immunotherapy

Early Peanut Introduction in Primary Care: Evaluation of a Multicomponent Intervention

Peanut allergy: risk factors, immune mechanisms, and best practices for oral immunotherapy success

Peanut allergy in toddlers

Safety and feasibility of peanut, tree nut, and sesame oral immunotherapy in infants and toddlers in a real-world setting

Peanut oral immunotherapy using an extensively heated and baked novel composition of peanuts

Is Component-Specific Antibody Testing Sufficient to Replace the Oral Food Challenge in the Diagnostics of Peanut-Sensitized Children? A Proof-of-Concept Study